In ME/CFS, the loss-of-function of TRPM3 is indicated by decreased calcium influx in NK cells, which can be ameliorated by low-dose naltrexone (LDN) treatment [16]. Here, TRPM3 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.